A n intracranial aneurysm (IA) is a weakened area in a cerebral artery wall that leads to abnormal dilation and may rupture, causing subarachnoid hemorrhage (SAH). The IA prevalence in the adult population is ≈3%.
A n intracranial aneurysm (IA) is a weakened area in a cerebral artery wall that leads to abnormal dilation and may rupture, causing subarachnoid hemorrhage (SAH). The IA prevalence in the adult population is ≈3%. 1 The overall annual incidence of SAH in developed countries is ≈10 per 100 000. 2 In the United States alone, there are roughly 30 000 aneurysmal SAH cases per year. 2, 3 Despite treatment advances, the mortality of aneurysmal rupture is high, and survivors experience high morbidity. [4] [5] [6] [7] [8] A family history, female sex, smoking, hypertension, and heavy alcohol consumption are significant risk factors for IA or SAH.
8,9
In a subset of patients, genetic factors play a role in IA pathogenesis. It is known that 7% to 20% of patients have a positive family history and first-degree relatives are at increased risk, regardless of ethnic background. [10] [11] [12] [13] [14] [15] [16] Further, a genetic syndrome, Autosomal-Dominant Polycystic Kidney Disease (ADPKD), predisposes patients to IA formation (although the vast majority of familial and sporadic IA patients do not
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have ADPKD or other defined syndromes). 17 Nearly all cases of ADPKD are caused by mutations in either polycystin 1 (PKD1) or polycystin 2 (PKD2) that have a range of functions from forming a mechanosensor that regulates intracellular calcium levels to being involved in focal adhesions and the extracellular matrix.
In the majority of patients, IA formation is a sporadic disease without a family history. In addition, high-risk variants affecting a subset of families may be heterogeneous. For that reason, population-based approaches like genome-wide association studies have identified low-risk loci only. 18, 19 Genomewide association studies frequently miss rare variants with high disease impact.
Spontaneous SAH is often, but not always, caused by IA rupture. 20 The Nordic twin study showed that SAH has a heritability estimate of 41% (95% confidence interval [CI] , 23.7%-55.5%); however, the vast majority of twins were discordant for SAH status. 21 The odds ratio for SAH is 51.0 (95% CI, 8.56-1117) when ≥2 affected first-degree relatives have SAH. 22 Mackey et al 23 recently reported their study of 21 twin pairs where at least one was affected by IA, and both agreed to be study participants. Eleven of 12 monozygotic twins were both positive for IA, irrespective of differential risk factors (smoking history and hypertension), while only 5 of 9 dizygotic twins were both affected, suggesting that genetics plays a role in at least some IA cases.
In familial studies, linkage analyses of single IA families or sibling pairs have mapped several susceptibility loci; however, no disease-causing IA mutation has been identified despite recent efforts, such as the multicenter Familial Intracranial Aneurysm Study. 24 Here, we report the identification of THSD1 (thrombospondin type 1 domain containing protein 1) mutations in both familial and sporadic IA cases and provide evidence using cell culture and animal models that THSD1 mutations contribute to disease.
Methods
Expanded methods are provided in the online-only Data Supplement.
Study Participants
Starting in 2000, IA patients treated at The University of Texas at Houston or the Brigham and Women's Hospital had thorough phenotypic characterization and screening to identify affected family members. The Institutional Review Boards approved this study at both institutions, and all study participants provided written informed consent. Over 500 IA probands and 100 affected families were enrolled and DNA samples obtained.
Those with a family history underwent genetic counseling, tracing of pedigrees with review of medical records, and screening of unaffected members using brain magnetic resonance angiography (MRA). Only those subjects with IA documented by medical records or a positive result on MRA screening were designated as affected. All subjects with fusiform dilatations caused by atherosclerosis or acute dissection, arterial ectasia, fibromuscular dysplasia, other cerebrovascular abnormalities, and a defined or a suspected genetic condition (ADPKD) were excluded. We excluded one subject who developed IA after cranial radiation (which has been associated with increased incidence of IA). 25 In addition, we excluded subjects with small, possible aneurysms that were not validated on subsequent imaging.
All positive subjects had an aneurysmal dilatation in a normal artery with a risk for rupture. They were classified by anatomic shape as saccular or fusiform aneurysm (Figure 1 ). Both were considered equivalent findings. For this study, we analyzed 35 family members from a European-American family (IA001), 507 unrelated IA patients and their families, and 305 controls with no known intracranial disease by medical history. We had information on rupture status for most of these patients. For those with known status, 52.2% had unruptured IA and 47.8% suffered SAH.
The control cohort was recruited at The University of Texas Medical School at Houston or the Brigham and Women's Hospital in Boston. No diagnostic tests were performed to exclude the presence of IAs in controls.
Detection of Mutations
Blood or saliva samples were collected from study participants, and genomic DNA was extracted using standard methods or DNA purification kits (Flexigene or Oragene). In our previous study, linkage analysis in family IA001 identified an IA susceptibility locus that maps to 13q14-21. 26 In the current study, we have characterized this family further using genome-wide whole exome sequencing and copy number analysis.
Copy number analysis was performed on III-9 and IV-14 using the NimbleGen Human CGH 385K Whole-Genome Tiling microarray. Exome analysis was performed on IV-6 and IV-15 using the NimbleGen Sequence Capture 2.1 Exome Array and the Illumina Genome Analyzer. All coding exons and closely flanking intronic regions in THSD1 (NM_018676) were sequenced in 507 IA probands and 305 controls via standard methods. Public data from the Exome Sequencing Project and the ExAC were used to assess allelic frequency of identified variants.
Immunofluorescence and Histopathologic Analyses in Mice
Immunofluorescence and histopathologic analyses were performed on brain sections from the previously described Thsd1-Venus mouse strain.
27 Frozen brain sections were stained with 4′,6-diamidino-2-phenylindole, anti-Venus, and anti-CD31 or anti-smooth muscle actin (SMA). Paraffin-embedded brain sections were stained with hematoxylin and eosin stain.
Functional Analyses
Knockdown of the THSD1 ortholog in zebrafish, LOC797520 (XM_001337954), was performed using a Morpholino oligomer (MO) (5′-GCAAGCATGCATTCTTACCAAATCC-3′) designed against the splice acceptor of exon 2. An MO from within the gene served as negative control (5′-AGACTTTCTGAGAAACTGGGCCTCT-3′). Different MO dosages were injected into zebrafish at the one-cell stage (n=53-70 per group). Images of live embryos at 48 hours post fertilization were obtained at 20× magnification using a Nikon TE2000 microscope. The Thsd1-Venus reporter knockin mice and their wild-type littermates were followed up to 6 months after birth. Brain magnetic resonance imaging and MRA were performed using a 9.4 Tesla Biospec 94/20 spectrometer.
THSD1 and negative control knockdown via transfection of siRNA (Stealth siRNA HSS148179 or Negative Control siRNA 12935-300; Life Technologies) was validated in cultured human umbilical vein endothelial cells by Western, and cell morphology was visualized by light microscopy. Effects on focal adhesion proteins (paxillin, phosphorylated focal adhesion kinase, and vinculin) were evaluated by immunofluorescence. Cell adhesion rescue experiments were performed on endogenous THSD1-depleted cells by siRNA cotransfection with the pCR3.1 vector carrying wild-type and mutant forms of THSD1 (L5F, R450X, R460W, E466G, G600E, P639L, T653I, and S775P) that were engineered to be siRNA resistant by site-directed, silent mutagenesis (G993 and G996). THSD1 and talin interaction was assayed by coimmunoprecipitation. Identification of the THSD1 (thrombospondin type 1 domain containing protein 1) R450X mutation in a large family with intracranial aneurysm (IA) and the spectrum of THSD1 rare variants. A, Pedigree of family IA001. Squares represent males; circles, females; black symbols, affected persons; white symbols, unaffected persons; gray symbols, unknown phenotype; and + and − symbols, R450X mutation carriers and noncarriers, respectively, as identified by sequencing. Slashes denote deceased individuals. Of the 9 affected individuals, 3 had subarachnoid hemorrhage (III-9, IV-15, and IV-17) while the rest had unruptured intracranial aneurysms. B, THSD1 (Continued )
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Statistical Analysis
The chi-squared test with Yates' correction was used to compare the frequency of rare THSD1 loss-of-function variants in our 507 IA patient cohort between European cases and controls (http://graphpad. com/quickcalcs/contingency1.cfm). The 95% CI for the proportion of IA and aneurysmal SAH in our cohort was calculated according to methods described by Robert Newcombe without a continuity correction (http://vassarstats.net/prop1.html). 28 The difference in frequency of intracranial hemorrhage between control MO-and LOC797520 MO-injected zebrafish was performed by chi-squared test. Differences in cerebral ventricular and whole brain volumes between the Thsd1 mutant and wild-type mouse groups were analyzed using the Welch two-sample t test. All in vitro experiments were performed in triplicates and repeated at least 3 times. Statistical data are presented as means with standard errors unless otherwise stated. The unpaired t test was used for group comparisons.
Results
IA001 Family
To identify an associated mutation, a large family with 9 members with IAs was characterized in detail (IA001; Figure 1A ; Table I in the online-only Data Supplement). The mean (±SD) age at IA diagnosis was 46.7±12.2. The proband (III-9) presented with SAH and 2 other family members IV-15 and IV-17 also had SAH. Unruptured intracranial aneurysms were determined by either medical history or MRA screening. Individuals were considered IA-negative after MRA screening. Two obligate carriers, III-3 and III-6, died of lung cancer and myocardial infarction at ages 77 and 69 years, respectively, without autopsies or MRA screens. Arterial dissections were present in 2 family members: a cervical carotid artery dissection (IV-6) and a coronary artery dissection (V-2). Smoking and hypertension data were available for 16 genotyped family members with known IA status (7 unaffected/9 affected). For the 7 family members without IA, 3, 2, 2, and 0 patients had a history of smoking, hypertension, both, and neither, respectively. For the 9 family members with IA, the numbers were 4, 2, 1, and 2, respectively. These modifiable risk factors in the IA001 family did not associate preferentially with IA versus non-IA status.
Although a dissection can precede the development of fusiform aneurysms, 20 these findings were not sufficient to be classified as positive. No clinical features associated with any other genetic syndrome were observed in the family.
Mutation Analyses
To define an associated mutation in the IA001 family, whole exome sequencing was performed on 2 affected family members (IV-6 and IV-15), identifying 53 heterozygous shared variants that alter protein sequences with minor allele frequencies <0.1% in controls. Of particular interest, a nonsense mutation (R450X) was identified in THSD1 gene (13:52952757, c.1348 C>T, NM_018676.3) that maps to 13q14.3. THSD1 ( Figure 1B ) encodes a transmembrane protein with a signal peptide (residues 1-24), extracellular domain (residues 25-413), and an intracellular domain (residues 435-852). The R450X mutation leads to a truncated protein that lacks the intracellular domain. Segregation of R450X allele in all affected family members was noted ( Figure 1A ) with an logarithm of odds (LOD) score of 4.69 (disease frequency =0.032; penetrance=100%; R450X allele frequency =0.001). The variant was heterozygous in all affected people, obligate carriers, and 3 members with unknown clinical status (III-12, IV-8, and V-2). This mutation was absent in unaffected relatives, our control cohort (n=305), and 89 040 chromosomes in the ExAC database. The R450X THSD1 variant cosegregates with disease in all 22 cases with known IA status in the IA001 family. For 16 members of the IA001 family, we had data relative to smoking history and hypertension. All 7 unaffected members had a smoking history, hypertension, or both. For the 9 affected members with IA, 7 of 9 had a smoking history, hypertension, or both. Of note, 2 family members (IV-6 and V-2) who carried the R450X THSD1 mutation had arterial dissections, suggesting that THSD1 loss may also be associated with dissections at low penetrance. No copy number variants were identified.
To interrogate the significance of THSD1 variants more broadly in IA, sequencing of all THSD1 coding exons and intron-exon boundaries was performed in 507 unrelated IA patients. Seven rare THSD1 heterozygous variants (<0.2% minor allele frequencies in controls) were identified, all encoding missense residues: L5F in 2 probands and R460W, E466G, G600E, P639L, T653I, and S775P in one proband each ( Figure 1B ; Table I in the online-only Data Supplement). The proband carrying E466G had an affected daughter with the inherited variant. The other probands had sporadic disease. L5F, P639L, and S775P were absent in 89 040 control chromosomes from the ExAC database, while R460W, E466G, G600E, and T653I were present in 2, 16, 45, and 6 control chromosomes, respectively (Table II in the online-only Data Supplement). These THSD1 mutations/rare variants were highly enriched in our IA patient cohort relative to 89 040 chromosomes in ExAC database (P<0.0001). Similarly, the 3 THSD1 mutations (R460W, E466G, and S775P) identified in known SAH individuals from our IA cohort were enriched relative to ExAC database (P<0.0001). L5F, R460W, E466G, G600E, and T653I are evolutionarily conserved amino acids Figure 1 Continued. rare variants in unrelated IA patients (red) and in control individuals (blue) in relation to numbered exons and protein domains. THSD1 control variants are from the NHLBI GO Exome Sequencing Project. Circles indicate predicted phosphorylation sites; and triangles, predicted N-glycosylation sites. C, THSD1 alignments highlight evolutionary conservation of substituted amino acids. D, Aneurysm images in patients with THSD1 variants. On the left, a digital subtraction angiogram shows a 9-mm right ophthalmic artery saccular aneurysm in subject III-9 of family IA001 with the R450X mutation. This aneurysm is termed saccular because the neck (black arrow) arises from an arterial branch point, the internal carotid artery (at the base of the aneurysm neck), and the ophthalmic artery (red arrow). On the right, a magnetic resonance angiogram shows a 3-mm right superior cerebellar artery aneurysm in patient NR0756 with sporadic disease and with the P639L variant. This aneurysm is defined as fusiform, because it arises from the trunk of the superior cerebellar artery (red arrow). The white arrow indicates the branch point between the basilar artery and the superior cerebellar artery. The aneurysm neck (black arrow) arises just distal to this branch point. Both represent weakened areas of the arterial wall that can rupture. CR indicates cysteine-rich region; NHLBI GO, National Heart, Lung, and Blood Institute Grand Opportunity; TM, transmembrane domain; and TSP1, thrombospondin type 1 repeat.
by guest on September 1, 2017 http://stroke.ahajournals.org/ Downloaded from ( Figure 1C ) that are predicted by PolyPhen2 and SIFT to be functionally significant.
Thsd1 Expression in the Mammalian Brain
Because THSD1 variants are implicated in IA, we investigated the expression pattern of Thsd1 in the mammalian brain by using a genetically engineered mouse model, where the knockin of the fluorescent Venus reporter at the Thsd1 locus results in a Thsd1 knockout.
27 Thsd1-Venus expression colocalized with the endothelial cell marker, CD31, indicating endothelial-specific expression of Thsd1 in cerebral arteries (Figure 2 ).
Loss of Thsd1 Expression in Zebrafish and Mice Disrupts the Cerebrovasculature
To establish the role of THSD1 in IA, 2 loss-of-function animal models were used. A zebrafish model was generated by embryonic injection of an antisense morpholino oligonucleotide at various concentrations that targets the splice acceptor site of exon 2 of the zebrafish thsd1 ortholog (LOC797520). The loss of thsd1 caused intracranial hemorrhages by 48 hours post fertilization in a dose-dependent manner ( Figure 3A) , while embryos injected with control MO were unaffected ( Figure 3B ). At each dose, the difference in hemorrhage rates between control MO-and LOC797520 MO-injected zebrafish was significant (P<0.001). The majority of thsd1-morphant zebrafish did not survive to adulthood. Corresponding MRA imaging showed poor perfusion in mutant mice with the most marked hydrocephaly ( Figure 4A ), suggesting increased intracranial pressure in these animals. No aneurysms were noted, and these scans were insufficiently sensitive to determine whether SAH occurred in the mouse brains.
Among the 185 mutant and 74 wild-type mice in the colony, 5 heterozygotes died by 4 weeks (none of the wild-types). Gross examination at autopsy revealed massive cerebral bleeding in an SAH pattern ( Figure 4B ). In addition, 5 mutant and 3 control mice were euthanized for histological analysis at 16 weeks of age. Both SAH and ventricular enlargement was noted in 1 of 2 Thsd1
Venus/+ and 1 of 3 Thsd1 Venus/Venus mice but not wild-type littermates (n=3; Figure 4C 
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A prior study in human lung fibroblasts suggested that THSD1 interacts with talin, 28 a key component of focal adhesions that mechanically link the intracellular actin bundles and integrin receptors that bind to the extracellular matrix. To test the hypothesis that THSD1 is involved in focal adhesions, THSD1 was analyzed in endothelial cells using loss-offunction and rescue experiments. Immunoblot confirmed THSD1 protein expression in cultured human umbilical vein endothelial cells and validated a THSD1-targeting siRNA ( Figure 5A ). Although cotransfection of treated cells with a vector containing siRNA-resistant wild-type THSD1 open reading frame restored THSD1 levels ( Figure 5A ), the expression of the other mutants was variable. Notably, the L5F mutant in the signal peptide resulted in undetectable protein levels, implicating rapid mutant mRNA or protein turnover.
In cells with the R450X construct, a truncated protein product was observed. Co-immunoprecipitation confirmed interaction of wild-type THSD1 and talin in human umbilical vein endothelial cells ( Figure 5B ). Cell adhesion to fibronectin, collagen IV, or laminin was unchanged with THSD1 knockdown (data not shown), but adhesion to collagen I was significantly reduced ( Figure 5C ). The cell adhesion defect was rescued by re-expression of wild-type THSD1 but not mutant THSD1 constructs. Compared with control cells, THSD1 siRNA-treated cells were significantly smaller with altered morphology and had fewer focal adhesions ( Figure 5D ). THSD1 knockdown impacted the expression/localization of focal adhesion proteins paxillin, vinculin, and phosphorylated FAK (Y397). Altogether, these results suggest that THSD1 mutations perturb endothelial focal adhesions, cell morphology, and cell adhesion in ways that may contribute partially to IA. Venus/+ mice. MRI analysis showed mild to severe dilatation of cerebral ventricles in a subset of Thsd1-mutant mice. MRA images showed poor visualization of blood flow in mice with severe ventricular dilatation. In wild-type animals, no ventricular dilatation was observed, and the vessels of the circle of Willis and emerging small vessels were well-delineated.
Right, Schematic diagrams of normal brain regions and cerebral arteries. B, The brain of a Thsd1
Venus/+ mouse that died suddenly at 9 weeks and that of a wild-type mouse euthanized at 9 weeks. Both brains were from nonperfused animals and imaged under the same dissecting microscope. Unlike the wild-type brain, the Thsd1
Venus/+ brain showed massive and diffuse cerebral hemorrhage. C, Hematoxylin and eosin (H&E) staining of brain slices from wild-type, Thsd1
Venus/+
, and Thsd1
Venus/Venus shows enlargement of lateral ventricles and extravasation of blood into the subarachnoid space (*) in a subset of mutant animals. No bleeding was noted in wild-type mice. 3V indicates third ventricle; ACA, anterior cerebral artery; BA, basilar artery; CC, corpus callosum; CCA, common carotid artery; D3V, dorsal third ventricle; EC, external capsule; HC, hippocampus; ICA, internal carotid artery; LV, lateral ventricle; MCA, middle cerebral artery; PCA, posterior cerebral artery; and VA, vertebral artery. The THSD1 open reading frame in pCR3.1 was engineered by silent mutagenesis to be siRNA-resistant and was used as a template for both WT and mutant THSD1 constructs. Co-transfection of THSD1 siRNA and the vector expressing wild-type THSD1 restored expression. In contrast, the L5F mutant resulted in undetectable protein expression, while R450X led to a truncated protein. C-terminal (C-ter) and N-terminal (N-ter)-targeting THSD1 antibodies. B, THSD1 and talin coimmunoprecipitate each other in HUVEC cells. Cell lysates of HUVECs transfected with WT THSD1 vector were subjected to immunoprecipitation (IP) with either an anti-C-ter THSD1 antibody (left) or anti-talin antibody (right) and immunoblotted with anti-talin, anti-C-ter THSD1, or anti-GAPDH antibody. C, Cell adhesion defects to collagen I in THSD1 siRNA-treated cells are rescued by cotransfection of siRNA-resistant wild-type but not variant THSD1 from intracranial aneurysm (IA) patients. * and ** denotes P<0.05 and P<0.001, respectively. D, Top, light microscopy imaging and immunofluorescence analyses of cells treated with a control or THSD1 siRNA; Bottom, quantification for cell areas (left) and focal adhesion numbers (right). Cell peripheries are shown in blue. In immunofluorescence staining, cells were stained with anti-C-ter THSD1, anti-paxillin, anti-pFAK (phosphorylated FAK; Y397), and anti-vinculin antibodies. A significant reduction in cell size and focal adhesion number was observed in THSD1 siRNA-treated cells.
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Discussion
We discovered in a large family a THSD1-truncating mutation (R450X) that segregated with disease. This mutation was present in all 9 affected cases (3 SAH and 6 unruptured intracranial aneurysms) and was absent in all 13 unaffected cases. In 8 unrelated probands, including those with sporadic disease, we identified THSD1 missense mutations that either exist in the signal peptide (L5F in 2 probands) or cluster in the intracellular region (R460W, E466G, G600E, P639L, T653I, and S775P). Overall, THSD1 mutations/rare variants that adversely affected protein function were found in 1.6% (95% CI, 0.8%-3.1%) and 1.9% (95% CI, 0.6%-5.3%) of total IA (507) and known SAH (162) cases, respectively, in our patient cohort. Therefore, other genetic and modifiable risk factors are primarily responsible for the vast majority of IA and SAH cases. We analyzed 2 animal models to assess the consequence of Thsd1 loss. Thsd1
Venus/+ mice suffered increased mortality and cerebral hemorrhage localized to the subarachnoid space. Zebrafish developed intracranial hemorrhaging in a dosedependent manner on thsd1 morpholino treatment. Recent work from Haasdijk et al 29 with a distinct thsd1 morpholino has independently confirmed our zebrafish results.
We did not observe IA formation in either model, although we can infer the presence of an aneurysm or other type of arterial weakening because of the hemorrhaging observed. It may be that our methods were inadequate to detect small aneurysms or that IA ruptured shortly after formation in these vertebrate model organisms. In human patients, it is known that small aneurysms, usually <3 mm in size, cannot be adequately assessed by MRA. 30 The arteries in mice are significantly smaller than those in human patients, and the aneurysms are likely to be smaller as well. Further, even histological sections cannot examine every part of the arteries, and therefore, small aneurysms might have been missed. It is also possible that mice and zebrafish do not develop aneurysms at all, but exhibit arterial weakness in a different manner.
Our data show prominent Thsd1 expression in endothelial cells in murine cerebral arteries and highlight the significance of this protein in endothelial cell focal adhesion and attachment. THSD1 knockdown weakens endothelial cellextracellular matrix binding as determined by cell culture studies. We also show that THSD1 interacts with talin. Of note, talin inactivation in endothelial cells had been shown to cause severe hemorrhaging in mouse embryos. 31 Taken together, these data suggest that talin and THSD1 interact to tether endothelial cells to the underlying basement membrane (see Figure I in the online-only Data Supplement for a model). The cellular adhesion defects associated with THSD1 loss are rescued by the re-expression of wild-type THSD1 but not the mutant open reading frames identified in our IA subjects.
Other research supports the importance of endothelial cell function in IA pathogenesis; loss of endothelial-specific expression of Sox17 promotes IAs in an elastase-treated hypertension mouse model. 32 Further, THSD1 shares some similarities to PKD1 and PKD2, 2 genes whose mutation causes ADPKD and increases IA risk. 17 In addition to a role as a mechanosensor, PKD1 and PKD2 form a complex that is involved in focal adhesion and cell-extracellular matrix interactions.
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The significance of THSD1 mutations in other aneurysm types or more broadly in cardiovascular pathogenesis remains unclear. In our IA cohort, other types of clinical pathology were rare; however, in the IA001 family, 2 R450X patients had arterial dissections. It is possible that THSD1 defects are associated with acute dissections.
Overall, these results suggest that defects in THSD1 may lead to IA formation and ultimately SAH, potentially via the disruption of endothelial cell adhesion to the extracellular matrix in cerebral arteries. These findings define several rare, high-risk genetic variants in THSD1 for IA and note a novel pathogenic pathway for a disease whose etiology had been poorly understood. Hospital had thorough phenotypic characterization and screening to identify affected family members. Over 500 probands, and 100 affected families were enrolled. DNA samples were obtained; those with a family history underwent genetic counseling, tracing of pedigrees with review of medical records, and screening of unaffected members using brain Magnetic Resonance Angiography (MRA). We only designated as affected those patients with a do novo weakening of the arterial wall. We excluded fusiform dilatations caused by atherosclerosis or dissection, arterial ectasia, fibromuscular dysplasia, or other cerebrovascular abnormalities; and all subjects with a defined or suspected genetic condition (ADPKD, Ehlers-Danlos syndrome type IV, neurofibromatosis type 1, Loeys-Dietz syndrome). We also excluded subjects with small, possible aneurysms not validated on subsequent imaging, and one subject who developed IA following cranial radiation (which has been associated with increased incidence of IA 1 ).
All positive subjects had an aneurysmal dilatation in a normal artery with a risk for rupture. By anatomical shape, they were classified as "saccular aneurysm" -arising from an arterial branch point -or "fusiform aneurysm" -arising from the side wall of an artery (Fig. I ). Both were considered equivalent findings. We analyzed 35 family members from family IA001 (Fig. IA) . The affection status of individuals with clinical signs of intracranial aneurysm was confirmed with medical records or through radiological or surgical examinations. For individuals with positive MRA screening results, cerebral angiography was performed to determine need for treatment. Individuals with negative MRA results and spouses of family members were scored as unaffected. 4 We also analyzed 507 unrelated IA patients and their families, and 305 controls with no intracranial disease by medical history. The 507 IA patients consisted of 367 (72.4%) females and 140 (27.6%) males. 
DETECTION OF MUTATIONS
Blood or saliva samples were collected from study participants and genomic DNA was extracted using standard methods or using DNA purification kits (Flexigene or Oragene).
Genome-wide whole exome sequencing and copy number analysis were performed in family IA001 in which a susceptibility locus in 13q14-21 was identified. 2 For copy number analysis, genomic DNA (2.5 µg)
from subjects III-9 and IV-14 were each analyzed alongside with human reference DNA consisting of a pool of DNA from normal lymphocytes from three healthy females, on a NimbleGen Human CGH 385K
Whole-Genome Tiling microarray (Roche NimbleGen, Inc) ,which provided measurements from 385,000 unique genomic loci. All sample and data processing were performed by NimbleGen Systems, Inc.
Genomic breakpoints were mapped using the segMNT v1.1 CGH segmentation analysis algorithm. Three window sizes (approximately 60,000; 120,000 and 300,000 base pairs) were further used for analysis.
Thresholds for averaged log2 ratio data were set to 0.1 and -0.1 for gains and losses, respectively. All coding exons (2 to 5) and closely-flanking intronic regions in THSD1 were sequenced in 507 intracranial aneurysm probands and 305 controls by means of standard methods. THSD1 was also sequenced in the proband from IA001 family as positive control. DNA amplifications were carried out using THSD1-specific primers and bidirectional sequencing was by performed using Big Dye chemistry.
The products were purified using CleanSEQ magnetic beads (Agencourt) and analyzed on the ABI3730xl
Genetic Analyzer (Applied Biosystems 
